The role of social support in functional status to a diagnosis of cancer was examined in 84 patients with breast cancer. Multivariate techniques were used to assess the relationships among the dimensions of social support, as measured by the Multidimensional Scale of Perceived Social Support (MSPSS), and functional status, assessed with the Inventory of the Functional Status Cancer (IFSA-CA). The results indicated significant independent associations between support and functional status outcomes, underscoring the importance of examining social support to evaluate functional status of patients. Nurses cognizant of breast cancer survivors challenges and concerns in areas of social support and are in a unique position to enhance functional status.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Upper cervical spinal cord atrophy in MS: Sex, menopause, and neurodegeneration.
Mult Scler
January 2025
Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Background: Spinal cord (SC) atrophy is a key imaging biomarker of progressive multiple sclerosis (MS). Progressive MS is more common in men and postmenopausal women.
Objective: Investigate the impact of sex and menopause on SC measurements in persons with MS (pwMS).
Palliative care needs and quality of life among adults with advanced chronic illnesses in low-income communities of Bangladesh.
BMC Palliat Care
January 2025
College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Objectives: Palliative care (PC) is an interdisciplinary approach aimed at improving the physical, psychological, and spiritual well-being of patients and families affected by life-threatening diseases. This study aimed to investigate the need for PC among critically ill patients and their quality of life (QOL) in low-income groups in Bangladesh.
Methods: This cross-sectional study was conducted at four healthcare facilities from March to April 2023, involving 553 registered patients with advanced chronic conditions.
Construction of cuproptosis-related genes risk model predicts the prognosis of Uterine Corpus Endometrial Carcinoma.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint, Guangzhou, 510000, China.
Cuproptosis, a recently discovered form of cell death, has emerged as a crucial player in tumor development, although its role in uterine corpus endometrial carcinoma (UCEC) remains inadequately explored. This study aims to identify prognostically relevant cuproptosis-related genes in endometrial cancer. Cuproptosis-related genes were sourced from previously published studies and the FerrDb database.
View Article and Find Full Text PDFA lower atherogenic index of plasma was associated with a higher incidence of sarcopenia.
Sci Rep
January 2025
Department of Geriatrics, The Third People's Hospital of Yunnan Province, The Second Affiliated Hospital of Dali University, 292 Beijing Road, Kunming, 650011, Yunnan Province, China.
Sarcopenia is an age-related muscle senescence disease that leads to functional limitations, physical disability and premature death in older adults. Atherogenic index of plasma (AIP) is a novel indicator of atherosclerotic status based on triglycerides and high-density lipoprotein cholesterol. The aim of this study was to investigate the association between AIP and new-onset sarcopenia and its components among middle-aged and older adults in a Chinese community.
View Article and Find Full Text PDFA Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Clin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!